Influenza virosomes supplemented with GPI-0100 adjuvant: A potent vaccine formulation for antigen dose sparing

Medical Microbiology and Immunology

Volumn 203, Issue 1, 2014, Pages 47-55

  Liu, Heng ^a   De Vries Idema, Jacqueline ^a   Ter Veer, Wouter ^a   Wilschut, Jan ^a   Huckriede, Anke ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

GPI 0100; Influenza vaccine; Subunit; Virosome

Indexed keywords

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, VIRAL; CELL LINE; DISEASE MODELS, ANIMAL; DOGS; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; ORTHOMYXOVIRIDAE INFECTIONS; SAPONINS; VACCINES, SUBUNIT; VACCINES, VIROSOME;

EID: 84894289349     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-013-0313-2     Document Type: Article

References (40)

1. Subbarao K, Joseph T (2007) Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 7:267-278
2. Ellebedy AH, Webby RJ (2009) Influenza vaccines. Vaccine 27(Suppl 4):D65-D68
3. Nichol KL, Treanor JJ (2006) Vaccines for seasonal and pandemic influenza. J Infect Dis 194(Suppl 2):S111-S118
4. Beyer WE, Nauta JJ, Palache AM, Giezeman KM, Osterhaus AD (2011) Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine 29:5785-5792
5. Beyer WE, Palache AM, Osterhaus AD (1998) Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clin Drug Investig 15:1-12
6. Leroux-Roels G (2010) Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28(Suppl 3):C25-C36
7. Durando P, Iudici R, Alicino C, Alberti M, de Florentis D, Ansaldi F et al (2011) Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum Vaccin 7(Suppl):29-40
8. Liu H, Bungener L, ter Veer W, Coller BA, Wilschut J, Huckriede A (2011) Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines. Vaccine 29:2037-2043
9. Liu H, Patil HP, de Vries-Idema J, Wilschut J, Huckriede A (2012) Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100. PLoS ONE 7:e52135
10. Liu H, Patil HP, de Vries-Idema J, Wilschut J, Huckriede A (2013) Evaluation of mucosal and systemic immune responses elicited by GPI-0100-adjuvanted influenza vaccine delivered by different immunization strategies. PlosOne 8:e69649
11. Baz M, Samant M, Zekki H, Tribout-Jover P, Plante M, Lanteigne AM et al (2012) Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. Clin Vaccine Immunol 19:209-218
12. Marciani DJ, Press JB, Reynolds RC, Pathak AK, Pathak V, Gundy LE et al (2000) Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine 18:3141-3151
13. Marciani DJ, Reynolds RC, Pathak AK, Finley-Woodman K, May RD (2003) Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. Vaccine 21:3961-3971
14. Huckriede A, Bungener L, Daemen T, Wilschut J (2003) Influenza virosomes in vaccine development. Methods Enzymol 373:74-91
15. Stegmann T, Morselt HW, Booy FP, van Breemen JF, Scherphof G, Wilschut J (1987) Functional reconstitution of influenza virus envelopes. EMBO J 6:2651-2659
16. Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J, Daemen T (2005) Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 23:1232-1241
17. Wilschut J (2009) Influenza vaccines: the virosome concept. Immunol Lett 122:118-121
18. Bungener L, Serre K, Bijl L, Leserman L, Wilschut J, Daemen T et al (2002) Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20:2287-2295
19. Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM et al (2005) The virosome concept for influenza vaccines. Vaccine 23(Suppl 1):S26-S38
20. Gluck R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr (1994) Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344:160-163
21. Conne P, Gauthey L, Vernet P, Althaus B, Que JU, Finkel B et al (1997) Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 15:1675-1679
22. Schaad UB, Buhlmann U, Burger R, Ruedeberg A, Wilder-Smith A, Rutishauser M et al (2000) Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob Agents Chemother 44:1163-1167
23. Kanra G, Marchisio P, Feiterna-Sperling C, Gaedicke G, Lazar H, Durrer P et al (2004) Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 23:300-306
24. de Bruijn IA, Nauta J, Cramer WC, Gerez L, Palache AM (2005) Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 23(Suppl 1):S39-S49
25. Herzog C, Hartmann K, Kunzi V, Kursteiner O, Mischler R, Lazar H et al (2009) Eleven years of Inflexal V - a virosomal adjuvanted influenza vaccine. Vaccine 27:4381-4387
26. Calcagnile S, Zuccotti GV (2010) The virosomal adjuvanted influenza vaccine. Expert Opin Biol Ther 10:191-200
27. Esposito S, Marchisio P, Montinaro V, Bianchini S, Weverling GJ, Pariani E et al (2012) The immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥ 6 to < 36 months: data from a randomized, phase III study. Vaccine 30:7005-7012
28. de Vries JJ, Bungener L, Ter Veer W, van Alphen L, van der Ley P, Wilschut J et al (2009) Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. Vaccine 27:947-955
29. Peterson GL (1977) A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83:346-356
30. Sanders MT, Brown LE, Deliyannis G, Pearse MJ (2005) ISCOM-based vaccines: the second decade. Immunol Cell Biol 83:119-128
31. Sun HX, Xie Y, Ye YP (2009) ISCOMs and ISCOMATRIX. Vaccine 27:4388-4401
32. Deliyannis G, Jackson DC, Dyer W, Bates J, Coulter A, Harling-McNabb L et al (1998) Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. Vaccine 16:2058-2068
33. Sambhara S, Woods S, Arpino R, Kurichh A, Tamane A, Underdown B et al (1998) Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes. J Infect Dis 177:1266-1274
34. Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de Haan A (2012) Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS ONE 7:e36812
35. Stegmann T, Kamphuis T, Meijerhof T, Goud E, de Haan A, Wilschut J (2010) Lipopeptide-adjuvanted respiratory syncytial virus virosomes: a safe and immunogenic non-replicating vaccine formulation. Vaccine 28:5543-5550
36. Cox RJ, Pedersen G, Madhun AS, Svindland S, Saevik M, Breakwell L et al (2011) Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine 29:8049-8059
37. Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ (2011) Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respi Viruses 5:426-437
38. Madhun AS, Haaheim LR, Nilsen MV, Cox RJ (2009) Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine 27:7367-7376
39. Schlosser E, Mueller M, Fischer S, Basta S, Busch DH, Gander B et al (2008) TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26:1626-1637
40. Hamdy S, Elamanchili P, Alshamsan A, Molavi O, Satou T, Samuel J (2007) Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D, L-lactic-co-glycolic acid) nanoparticles. J Biomed Mater Res A 81:652-662